A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Patients with irritable bowel syndrome (IBS) are suggested to have an altered intestinal microenvironment. We therefore aimed to determine the intestinal microenvironment profile, based on faecal microbiota and metabolites, and the potential link to symptoms in IBS patients. The faecal microbiota was evaluated by the GA-mapTM dysbiosis test, and tandem mass spectrometry (GC-MS/MS) was used for faecal metabolomic profiling in patients with IBS and healthy subjects. Symptom severity was assessed using the IBS Severity Scoring System and anxiety and depression were assessed using the Hospital Anxiety and Depression Scale. A principal component analysis based on faecal microbiota (n = 54) and metabolites (n = 155) showed a clear separation between IBS patients (n = 40) and healthy subjects (n = 18). Metabolites were the main driver of this separation. Additionally, the intestinal microenvironment profile differed between IBS patients with constipation (n = 15) and diarrhoea (n = 11), while no clustering was detected in subgroups of patients according to symptom severity or anxiety. Furthermore, ingenuity pathway analysis predicted amino acid metabolism and several cellular and molecular functions to be altered in IBS patients. Patients with IBS have a distinct faecal microbiota and metabolite profile linked to bowel habits. Intestinal microenvironment profiling, based on faecal microbiota and metabolites, may be considered as a future non-invasive diagnostic tool, alongside providing valuable insights into the pathophysiology of IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724 · cited 1×
“com/products/ingenuitypathway-analysis, trial version accessed on 18 March 2020) [41] was used to identify biological networks associated with mean fold change values (IBS patients/healthy subject) for each of the analysed faecal metabolites.”
MethodGut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Agus, A., Planchais, J., & Sokol, H. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.003 · Cited by 3,180 · cited 1×
“Furthermore, microbial tryptophan catabolites are known to activate gut immune response via the aryl hydrocarbon receptor [48], potentially strengthening the intestinal barrier integrity [49].”
BackgroundMicrobial tryptophan catabolites in health and disease
Roager, H. M., & Licht, T. R. (2018) · Nature Communications · doi:10.1038/s41467-018-05470-4 · Cited by 2,236 · cited 1×
“Furthermore, microbial tryptophan catabolites are known to activate gut immune response via the aryl hydrocarbon receptor [48], potentially strengthening the intestinal barrier integrity [49].”
BackgroundFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835 · cited 1×
“These bacterial taxa have previously been associated with IBS, however not to any specific IBS subtype [14,59,60].”
BackgroundSelf-citationTap, J., Derrien, M., Törnblom, H., Brazeilles, R., Cools-Portier, S., Doré, J., Störsrud, S., Le Nevé, B., Öhman, L., & Simrén, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.049 · Cited by 642
Self-citationBrain gut microbiome interactions and functional bowel disorders
Mayer, E. A., Savidge, T., & Shulman, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.037 · Cited by 496 · cited 2×
“Growing evidence further indicates that IBS pathogenesis involves a dysregulated and bidirectional gut-brain interaction where microbiota and microbial metabolites influence neuro-immune crosstalk [1,20,46], and in return, the central nervous system influences the intestinal microenvironment [1].”
Backgroundtana, C., umesaki, Y., imaoka, A., handa, T., kanazawa, M., & fukudo, S. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01427.x · Cited by 474 · cited 1×
“In addition, IBS has been linked to an unbalanced gut microbiota profile [13–16] and possibly also to an altered metabolite profile [17,18], with links to GI [17,19] and psychological symptoms [20], at least in subsets of patients.”
BackgroundLongitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome
Mars, R. A. T., Yang, Y., Ward, T., Houtti, M., Priya, S., Lekatz, H. R., Tang, X., Sun, Z., Kalari, K. R., Korem, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.007 · Cited by 456
Gut Microbiota Profiling: Metabolomics Based Approach to Unravel Compounds Affecting Human Health
Vernocchi, P., Del Chierico, F., & Putignani, L. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01144 · Cited by 426 · cited 3×
“Altered production or availability of metabolites such as amino acids, short-chain fatty acids, vitamins, bile salts, lipids and organic acids, associated with microbial metabolism or host-microbial co-metabolism, could result in alteration of pathways involved in host physiology [9].”
BackgroundImmune regulation by microbiome metabolites
Kim, C. H. (2018) · Immunology · doi:10.1111/imm.12930 · Cited by 375
The Intestinal Microenvironment and Functional Gastrointestinal Disorders
Barbara, G., Feinle-Bisset, C., Ghoshal, U. C., Santos, J., Vanner, S. J., Vergnolle, N., Zoetendal, E. G., & Quigley, E. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.028 · Cited by 335 · cited 1×
“Despite inconsistencies, the overall picture indicates that subsets of IBS patients have an altered intestinal microenvironment [27].”
BackgroundSimrén, M., Törnblom, H., Palsson, O. S., van Tilburg, M. A. L., Van Oudenhove, L., Tack, J., & Whitehead, W. E. (2018) · Gut · doi:10.1136/gutjnl-2016-312361 · Cited by 254
Self-citationBosi, A., Banfi, D., Bistoletti, M., Giaroni, C., & Baj, A. (2020) · International Journal of Tryptophan Research · doi:10.1177/1178646920928984 · Cited by 221 · cited 1×
“Serotonin is known to promote motility, secretion and visceral hypersensitivity in IBS patients with diarrhoea [18,42,55] and, hence, drug development has to a large extent focused on 5-hydroxytryptamine (5-HT) receptor antagonist for symptom management [55].”
BackgroundParkes, G. C., Rayment, N. B., Hudspith, B. N., Petrovska, L., Lomer, M. C., Brostoff, J., Whelan, K., & Sanderson, J. D. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01803.x · Cited by 200
Colonic Transit Time and IBS Symptoms: What's the Link?
Törnblom, H., Van Oudenhove, L., Sadik, R., Abrahamsson, H., Tack, J., & Simrén, M. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.5 · Cited by 185 · cited 1×
“Irritable bowel syndrome (IBS) is a multifactorial disease involving a perturbed gut– brain interaction [1], visceral hypersensitivity [2], altered gastrointestinal (GI) motility [3], increased permeability, immune activation [4] and an altered gut microenvironment [5].”
BackgroundSelf-citationMazzawi, T., Lied, G. A., Sangnes, D. A., El-Salhy, M., Hov, J. R., Gilja, O. H., Hatlebakk, J. G., & Hausken, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194904 · Cited by 92 · cited 1×
“Previous reports evaluating the effects of faecal microbiota transplantation (FMT) from healthy subjects, described that FMT normalized either microbiota [61] or microbiota together with short-chain fatty acids [62] in IBS-D patients and improved IBS symptoms.”
BackgroundZhang, W.-X., Zhang, Y., Qin, G., Li, K.-M., Wei, W., Li, S.-Y., & Yao, S.-K. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i43.6416 · Cited by 32 · cited 3×
“More recently, reports focusing on intestinal metabolites [17,18], alongside studies integrating the gut microbiome and metabolome [22,24,25], as Figure 4.”
BackgroundShankar, V., Reo, N. V., & Paliy, O. (2015) · Microbiome · doi:10.1186/s40168-015-0139-9 · Cited by 26 · cited 3×
“, who previously described this joint classifier to facilitate diagnosis of IBS and differentiate paediatric IBS-D patients from age-matched controls [24].”
Background
Cited by
Advancing human gut microbiota research by considering gut transit time
Procházková, N., Falony, G., Dragsted, L. O., Licht, T. R., Raes, J., & Roager, H. M. (2023) · Gut · doi:10.1136/gutjnl-2022-328166 · Cited by 308
Chronic constipation and gut microbiota: current research insights and therapeutic implications
Xu, X., Wang, Y., Long, Y., & Cheng, Y. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgae112 · Cited by 32
Ahluwalia, B., Magnusson, M. K., Böhn, L., Störsrud, S., Larsson, F., Öhman, L., & Simrén, M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211048133 · Cited by 11
Self-citation
Metadata
- Authors
- Ahluwalia, B., Iribarren, C., Magnusson, M. K., Sundin, J., Clevers, E., Savolainen, O., Ross, A. B., Törnblom, H., Simrén, M., & Öhman, L.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-06-10
- Volume
- 10
- Issue
- 6
- Pages
- 1459
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3171878901
- Cited by
- 41
- References
- 19
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.